Cocrystal pharma presents positive data from u.s. phase 2a study of cc-31244 demonstrating ability to identify patients more likely to respond to ultrashort treatment of hcv

Cocrystal pharma presents positive data from u.s. phase 2a study of cc-31244 demonstrating ability to identify patients more likely to respond to ultrashort treatment of hcv.cocrystal pharma inc - results from phase 2a study demonstrated that eight of 12 patients achieved primary endpoint of sustained virologic response 12.cocrystal pharma inc - frequency of naÏve cd8+ t cells was lower while frequency of effector memory cd8+ t cells was higher in svr patients.cocrystal pharma inc - differences between frequency of naÏve cd8+ t cells and frequency of effector memory cd8+ t cells not statistically significant.
COCP Ratings Summary
COCP Quant Ranking